Chris Beyrer
Director, Duke Global Health Institute
Gary Hock Distinguished Professor in Global Health
Professor of Medicine
Research Professor of Global Health
Appointment:
Chris Beyrer
Director, Duke Global Health Institute
Gary Hock Distinguished Professor in Global Health
Professor of Medicine
Research Professor of Global Health
Chris Beyrer, MD, MPH, an internationally recognized epidemiologist who has worked on the front lines of HIV/AIDS and COVID-19 treatment and research, became director of the Duke Global Health Institute in August 2022.
Beyrer has led collaborative research on HIV epidemiology, prevention and treatment in Southeast Asia, Sub-Saharan Africa, and Eastern Europe and Central Asia for more than 30 years. He is past president of the International AIDS Society, the world’s largest body of HIV professionals, and currently serves as an advisor to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the HIV Vaccine Trials Network, the World Health Organization, and Physicians for Human Rights. The author of over 400 scientific papers, he was named in 2022 to the annual list of the world’s most cited scientists.
Before coming to Duke, Beyrer was the inaugural Desmond M. Tutu Professor of Public Health and Human Rights at the Johns Hopkins Bloomberg School of Public Health, where he served as associate director of the JHU Center for AIDS Research and the Center for Global Health. He was the founding director of the Center for Public Health and Human Rights. He received his medical degree from SUNY Downstate Health Sciences University and holds a Master of Public Health from Johns Hopkins Bloomberg School of Public Health. He was elected to the National Academy of Medicine in 2014 and serves on the Academy’s Board for Global Health and on the Committee for Human Rights.
Publications
-
Weyant C, Meyer JP, Bromberg D, Beyrer C, Altice FL, Goldhaber-Fiebert JD. Decarceration and COVID-19 infections in U.S. Immigration and Customs Enforcement detention facilities: a simulation modeling study. Lancet Reg Health Am. 2025 Feb;42:100971.Cooney EE, Stevenson M, Aguayo-Romero RA, Valera G, Poteat TC, Mayer KH, et al. Preference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study. AIDS Behav. 2024 Dec 5;Coelho SM, Rosen JG, Schulz G, Meek K, Shipp L, Singh C, et al. A decade of PrEP: the evolution of HIV pre-exposure prophylaxis content and sentiments in South African print news media, 2012-2021. Cult Health Sex. 2024 Dec;26(12):1618–34.Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, et al. Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024 Nov 22;79(5):1197–207.
See more publications at Scholars@Duke